Table 2 Mean difference (95% CI) in neurocognitive z-score associated with the second or third tertile of PCPhenoAge EAA compared to the first tertile stratified by exposure to CNS-directed therapy

From: Epigenetic age acceleration, telomere length, and neurocognitive function in long-term survivors of childhood cancer

 

Non-CNS-treateda n = 663

CNS-treatedb n = 750

Tertile 2 vs. 1

Tertile 3 vs. 1

Tertile 2 vs. 1

Tertile 3 vs. 1

β (95% CI)

p*

β (95% CI)

p*

β (95% CI)

p*

β (95% CI)

p*

Global cognition

        

 Verbal reasoning

0.01 (−0.19, 0.21)

0.973

−0.13 (−0.33, 0.07)

0.199

−0.15 (−0.33, 0.04)

0.210

−0.29 (−0.49, −0.09)

0.013

 Non-verbal reasoning

−0.03 (−0.17, 0.12)

0.973

−0.22 (−0.36, −0.07)

0.013

−0.07 (−0.23, 0.09)

0.395

−0.18 (−0.35, −0.01)

0.051

Academics

        

 Word reading

−0.002 (−0.11, 0.11)

0.973

−0.09 (−0.20, 0.02)

0.129

−0.09 (−0.21, 0.02)

0.210

−0.17 (−0.29, −0.05)

0.013

 Mathematics

−0.10 (−0.27, 0.07)

0.973

−0.16 (−0.33, 0.01)

0.129

−0.13 (−0.30, 0.05)

0.210

−0.17 (−0.36, 0.01)

0.068

Attention

        

 Sustained

0.13 (−0.08, 0.34)

0.478

−0.15 (−0.36, 0.06)

0.316

−0.05 (−0.27, 0.16)

0.799

−0.14 (−0.37, 0.09)

0.325

 Variability

0.001 (−0.21, 0.21)

0.990

−0.18 (−0.39, 0.03)

0.316

−0.10 (−0.29, 0.10)

0.799

−0.16(−0.37, 0.05)

0.325

 Commissions

0.09 (−0.11, 0.28)

0.520

−0.07 (−0.26, 0.13)

0.504

0.06 (−0.13, 0.25)

0.799

−0.08 (−0.28, 0.11)

0.408

 Focused attention

−0.12 (−0.31, 0.08)

0.478

−0.10 (−0.29, 0.09)

0.406

−0.03 (−0.23, 0.18)

0.799

−0.14 (−0.35, 0.08)

0.325

Processing Speed

        

 Visual-motor

0.01 (−0.16, 0.18)

0.888

−0.19 (−0.36, −0.02)

0.049

−0.07 (−0.24, 0.11)

0.808

−0.10 (−0.28, 0.08)

0.590

 Motor

0.07 (−0.15, 0.28)

0.888

−0.01 (−0.22, 0.20)

0.921

0.03 (−0.18, 0.23)

0.808

−0.02 (−0.23, 0.20)

0.867

Memory

        

 Span

0.17 (−0.02, 0.36)

0.289

−0.14 (−0.32, 0.05)

0.560

−0.08 (−0.25, 0.09)

0.350

−0.10 (−0.28, 0.08)

0.284

 New verbal encoding

0.05 (−0.16,0.25)

0.850

−0.06 (−0.26, 0.14)

0.771

−0.14 (−0.34, 0.06)

0.248

−0.20 (−0.42, 0.01)

0.234

 Short-term verbal recall

−0.10 (−0.30, 0.10)

0.649

−0.10 (−0.30, 0.09)

0.579

−0.13 (−0.32, 0.06)

0.248

−0.14 (−0.34, 0.07)

0.257

 Long-term verbal recall

−0.01 (−0.21, 0.19)

0.920

−0.03 (−0.23, 0.17)

0.784

−0.16 (−0.36, 0.05)

0.248

−0.18 (−0.40, 0.04)

0.234

Executive function

        

 Perseveration

0.13 (−0.10, 0.35)

0.801

−0.14 (−0.36, 0.09)

0.226

0.01 (−0.23, 0.24)

0.964

−0.01 (−0.26, 0.25)

0.968

 Working memory

0.08(−0.10,0.25)

0.801

−0.14 (−0.31, 0.04)

0.226

0.03 (−0.13, 0.19)

0.915

−0.07 (−0.24, 0.10)

0.540

 Cognitive switching/flexibility

0.004 (−0.24, 0.25)

0.973

−0.19 (−0.44, 0.05)

0.226

−0.19 (−0.45, 0.07)

0.584

−0.27 (−0.55, 0.00)

0.207

 Verbal fluency

0.01 (−0.20, 0.23)

0.973

−0.13 (−0.34, 0.07)

0.226

−0.06 (−0.24, 0.12)

0.915

−0.15 (−0.35, 0.04)

0.232

  1. EAA epigenetic age acceleration calculated used PCPhenoAge epigenetic clock.
  2. aModels are adjusted for sex, diagnosis age, BMI, physical activity, smoking, and high-dose IV methotrexate.
  3. bModels are adjusted for sex, diagnosis age, BMI, physical activity, smoking, cranial radiation dose, intrathecal methotrexate, high-dose IV methotrexate, high-dose cytarabine, and neurosurgery.
  4. *Adjusted for multiple comparisons using the false-discovery rate.